Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Hereditary leiomyomatosis and renal cell carcinoma"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Yeonjoo Choi, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Dalyong Kim, Jong Gwon Choi, Ja Young Seo, Inkeun Park, Jae Lyun Lee
Cancer Res Treat. 2019;51(4):1549-1556.   Published online March 25, 2019
DOI: https://doi.org/10.4143/crt.2019.086
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC.
Materials and Methods
We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Result
We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding.
Conclusion
This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.

Citations

Citations to this article as recorded by  
  • A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
    Ritesh R. Kotecha, Sahil D. Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J. Shah, Emily Feld, David H. Aggen, William Rafelson, Han Xiao, Maria I. Carlo, Darren R. Feldman, Chung-Han Lee,
    European Urology Oncology.2024; 7(4): 804.     CrossRef
  • Hereditary Renal Cancer Syndromes
    Grigory A. Yanus, Ekaterina Sh. Kuligina, Evgeny N. Imyanitov
    Medical Sciences.2024; 12(1): 12.     CrossRef
  • Fumarate Hydratase-Deficient Renal Cell Carcinoma—A Clinicopathological Study of a Series of 11 Cases
    Aswathy A. Menon, Swapnil Rane, Uma Sakhadeo, Gagan Prakash, Amit Joshi, Mahendra Pal, Amandeep Arora, Nilesh Sable, Aparna Katdare, Palak Popat, Priyamvada Maitre, Archi Agarwal, Vedang Murthy, Sangeetha B. Desai, Santosh Menon
    Indian Journal of Medical and Paediatric Oncology.2024;[Epub]     CrossRef
  • Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
    Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Jingjing Guo, Jianhui Chen, Yongquan Wang, Xinan Sheng, Haiying Dong, Xiaodong Liu, Xingming Zhang, Jiayu Liang, Haolin Liu, Jin Yao, Jiyan Liu, Yali Shen, Zhibin Chen, Zhengyu He, Yaodong Wang, N
    Clinical Cancer Research.2024; 30(11): 2571.     CrossRef
  • Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma
    Anna Caliò, Stefano Marletta, Lavinia Stefanizzi, Lisa Marcolini, Matteo Rotellini, Gabriella Serio, Elena Bariani, Caterina Vicentini, Serena Pedron, Filippo M. Martelli, Pietro Antonini, Matteo Brunelli, Guido Martignoni
    Modern Pathology.2024; 37(9): 100561.     CrossRef
  • Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
    Elena Chitoran, Vlad Rotaru, Sinziana-Octavia Ionescu, Aisa Gelal, Cristina-Mirela Capsa, Roxana-Elena Bohiltea, Madalina-Nicoleta Mitroiu, Dragos Serban, Giuseppe Gullo, Daniela-Cristina Stefan, Laurentiu Simion
    Cancers.2024; 16(14): 2590.     CrossRef
  • Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
    Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
    Cancer Research and Treatment.2024; 56(3): 721.     CrossRef
  • Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
    Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
    Journal of Pathology and Translational Medicine.2024; 58(4): 147.     CrossRef
  • Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma
    Isabella Portugal, Maria A. Clavijo-Salomon
    npj Precision Oncology.2024;[Epub]     CrossRef
  • Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
    Yunze Xu, Wen Kong, Ming Cao, Jieying Wang, Zaoyu Wang, Liang Zheng, Xiaoyu Wu, Rongrong Cheng, Wei He, Bo Yang, Baijun Dong, Jiahua Pan, Yonghui Chen, Jiwei Huang, Chen Jiang, Wei Zhai, Fangzhou Li, Ruohua Chen, Xiang Zhou, Guangyu Wu, Xiaochuan Geng, Ji
    European Urology.2023; 83(2): 163.     CrossRef
  • Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
    Alexius John, Lavinia Spain, Anis A. Hamid
    Current Oncology.2023; 30(1): 923.     CrossRef
  • CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds
    Alexey A. Lagunin, Anastasia V. Rudik, Pavel V. Pogodin, Polina I. Savosina, Olga A. Tarasova, Alexander V. Dmitriev, Sergey M. Ivanov, Nadezhda Y. Biziukova, Dmitry S. Druzhilovskiy, Dmitry A. Filimonov, Vladimir V. Poroikov
    International Journal of Molecular Sciences.2023; 24(2): 1689.     CrossRef
  • Fumarate Hydratase-deficient Renal Cell Carcinoma
    Yi-Hsuan Huang, Nan-Haw Chow, Yu-Ting Yu, Wen-Pin Su
    Journal of Cancer Research and Practice.2023; 10(1): 28.     CrossRef
  • Diseases of Hereditary Renal Cell Cancers
    Othon Iliopoulos
    Urologic Clinics of North America.2023; 50(2): 205.     CrossRef
  • Hereditary Leiomyomatosis and Renal Cell Cancer: A Case Report of Pilar Leiomyomatosis with History of Kidney Cancer and Review of the Literature
    Jee-Woo Kim, Jung-Won Shin, Anna Cho, Chang-Hun Huh
    Annals of Dermatology.2023;[Epub]     CrossRef
  • Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
    Xinfeng Hu, Congzhu Tan, Guodong Zhu
    Current Issues in Molecular Biology.2023; 45(6): 4763.     CrossRef
  • Hereditary predisposition to kidney cancer: cancer syndromes, multisystemic disorders, and nephropathies
    G. A. Yanus, A. G. Iyevleva, E. N. Suspitsin, A. V. Tumakova, E. V. Belogubova, S. N. Aleksakhina, A. V. Togo, E. N. Imyanitov
    Sechenov Medical Journal.2023; 14(2): 5.     CrossRef
  • Hereditary leiomyomatosis and renal cell cancer associated with metastatic rectal cancer
    Parikshit Padhi, Naga Praneeth Raja
    Current Problems in Cancer: Case Reports.2023; 11: 100257.     CrossRef
  • Unmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma
    Mirza Rameez Samar, Wajiha Khan, Yasmin Abdul Rashid, Azmina Tajuddin Vali Mohammad
    International Journal of Surgery Case Reports.2023; 113: 109054.     CrossRef
  • Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities
    Alexander S. Taylor, Stephanie L. Skala
    Urologic Oncology: Seminars and Original Investigations.2022; 40(12): 499.     CrossRef
  • Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female
    Nicolas Wyvekens, William J. Anderson, Young X. Kim, Mark Carter, Michelle S. Hirsch
    International Journal of Surgical Pathology.2022; 30(2): 184.     CrossRef
  • Response to the Letter to the Editor Entitled “Do We Have Sufficient Evidence to Define Prognosis for ‘Low-grade’ Fumarate Hydratase-deficient Renal Cell Carcinoma?”
    Steven C. Smith, Ameer Hamza, Deepika Sirohi, Mahul B. Amin
    Advances in Anatomic Pathology.2022; 29(3): 181.     CrossRef
  • Hereditary Renal Cell Carcinoma
    Scott J. Dawsey, Shilpa Gupta
    Kidney Cancer.2022; 6(2): 83.     CrossRef
  • A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
    Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
    Clinical Genitourinary Cancer.2022; 20(5): 415.     CrossRef
  • Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
    Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, Peter J. Siska, Martin Thurnher, Renate Pichler
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome
    Guangyu Wu, Guiqin Liu, Jianfeng Wang, Shihang Pan, Yuansheng Luo, Yunze Xu, Wen Kong, Peng Sun, Jianrong Xu, Wei Xue, Jin Zhang
    Radiology.2022; 305(3): 631.     CrossRef
  • Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report
    Yasuhiro Iribe, Mitsuko Furuya, Yousuke Shibata, Masato Yasui, Makoto Funahashi, Junichi Ota, Hiromichi Iwashita, Yoji Nagashima, Hisashi Hasumi, Narihiko Hayashi, Kazuhide Makiyama, Keiichi Kondo, Reiko Tanaka, Masahiro Yao, Noboru Nakaigawa
    Familial Cancer.2021; 20(1): 75.     CrossRef
  • Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
    Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park
    Annals of Laboratory Medicine.2021; 41(2): 207.     CrossRef
  • Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
    Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindon
    Clinical Cancer Research.2021; 27(6): 1734.     CrossRef
  • Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
    Marianne Spengler, Megan Wheelden, Heath B. Mackley, Joseph J. Drabick
    JCO Precision Oncology.2021; (5): 664.     CrossRef
  • Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
    Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
    Cancers.2021; 13(9): 2170.     CrossRef
  • Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
    Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Pailleret
    European Journal of Cancer.2021; 151: 106.     CrossRef
  • Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
    Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Hereditary leiomyomatosis and renal cell cancer presenting as urothelial carcinoma
    Samuel B Reynolds, Rishi Charate, Quang L Nguyen, Padmini Moffett
    Journal of Onco-Nephrology.2021; 5(3): 178.     CrossRef
  • Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papillären Tumoren in der Niere
    N. Rupp, H. Moch
    Der Pathologe.2021; 42(6): 560.     CrossRef
  • To treat or not to treat: a clinical series of retinal arterial macroaneurysms
    Wan-Hua Cho, Wei-Yu Chiang, Chih-Hsin Chen, Hsi-Kung Kuo
    Medicine.2020; 99(5): e19077.     CrossRef
  • Bevacizumab/erlotinib

    Reactions Weekly.2020; 1798(1): 61.     CrossRef
  • On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
    Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
    American Society of Clinical Oncology Educational Book.2020; (40): 418.     CrossRef
  • Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
    Nicolas Wyvekens, Nadejda Valtcheva, Axel Mischo, Birgit Helmchen, Thomas Hermanns, Matthias Choschzick, Andreas M. Hötker, Anita Rauch, Beda Mühleisen, Dilara Akhoundova, Achim Weber, Holger Moch, Niels J. Rupp
    Genes, Chromosomes and Cancer.2020; 59(11): 611.     CrossRef
  • Fumarate hydratase as a therapeutic target in renal cancer
    Priyanka Kancherla, Michael Daneshvar, Rebecca A. Sager, Mehdi Mollapour, Gennady Bratslavsky
    Expert Opinion on Therapeutic Targets.2020; 24(9): 923.     CrossRef
  • Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma
    Shuheng Bai, YinYing Wu, Yanli Yan, Shuai Shao, Jiangzhou Zhang, Jiaxin Liu, Beina Hui, Rui Liu, Hailin Ma, Xiaozhi Zhang, Juan Ren
    Scientific Reports.2020;[Epub]     CrossRef
  • 8,352 View
  • 324 Download
  • 40 Web of Science
  • 41 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP